Melissa Pavilack

459 total citations
26 papers, 330 citations indexed

About

Melissa Pavilack is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Melissa Pavilack has authored 26 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Melissa Pavilack's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Melissa Pavilack is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Melissa Pavilack collaborates with scholars based in United States, Canada and Japan. Melissa Pavilack's co-authors include Ancilla W. Fernandes, Mark S. Walker, Janet L. Espirito, Eric Nadler, Kimmie McLaurin, Kellie Ryan, Mei Sheng Duh, Sally W. Wade, Ari M. Vanderwalde and Amanda M. Kong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and BMC Cancer.

In The Last Decade

Melissa Pavilack

23 papers receiving 324 citations

Peers

Melissa Pavilack

PRM

ONCOL

EPIDE

SURGE

Keisha A. Houston United States

Vishal Navani Canada

Jennifer M. Suga United States

Mitchell S. von Itzstein United States

Giovanni Zanotti United States

Sara Koo United Kingdom

Monica Jones United Kingdom

Chiharu Tanai Japan

Wolfgang Gleiber Germany

Andrew Loh United Kingdom

Keisha A. Houston United States

Melissa Pavilack

223 ×0.9

PRM

190 ×1.2

ONCOL

32 ×0.4

EPIDE

38 ×0.8

32 ×0.8

SURGE

Citations per year, relative to Melissa Pavilack Melissa Pavilack (= 1×) peers Keisha A. Houston

Countries citing papers authored by Melissa Pavilack

Since Specialization

Citations

This map shows the geographic impact of Melissa Pavilack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Pavilack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Pavilack more than expected).

Fields of papers citing papers by Melissa Pavilack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Pavilack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Pavilack. The network helps show where Melissa Pavilack may publish in the future.

Co-authorship network of co-authors of Melissa Pavilack

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Pavilack. A scholar is included among the top collaborators of Melissa Pavilack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Pavilack. Melissa Pavilack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hung, Anna, Kyung Min Lee, Patrick R. Alba, et al.. (2021). EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. Cancer Treatment and Research Communications. 27. 100327–100327. 2 indexed citations

Kong, Amanda M., Melissa Pavilack, Hairong Huo, et al.. (2021). Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. Journal of Medical Economics. 24(1). 328–338. 3 indexed citations

Nadler, Eric, et al.. (2020). Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy. 37(2). 946–954. 18 indexed citations

Epperla, Narendranath, Melissa Pavilack, Temitope Olufade, et al.. (2020). Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. Orphanet Journal of Rare Diseases. 15(1). 47–47. 7 indexed citations

Chiang, Anne C., Ancilla W. Fernandes, Melissa Pavilack, et al.. (2020). EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 20(1). 356–356. 23 indexed citations

Pokrzywinski, Robin, Pia S. Pannaraj, Jumi Yi, et al.. (2019). Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants. Clinical Pediatrics. 58(8). 837–850. 16 indexed citations

Subramaniam, Deepa S., Melissa Pavilack, Hairong Huo, et al.. (2019). P2.16-37 Impact of Brain Metastases on Healthcare Utilisation and Costs in Patients with NSCLC Treated with EGFR-TKIs. Journal of Thoracic Oncology. 14(10). S880–S880.

Subramanian, Janakiraman, Ancilla W. Fernandes, François Laliberté, et al.. (2019). The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer. 138. 131–138. 8 indexed citations

Ryan, Kellie, et al.. (2019). Treatment Patterns and Overall Survival among Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer. Future Oncology. 15(29). 3381–3393. 13 indexed citations

10.

Ryan, Kellie, Ancilla W. Fernandes, Rajeshwari Punekar, et al.. (2019). Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Medical Oncology. 36(3). 24–24. 19 indexed citations

11.

Ryan, Kellie, Ancilla W. Fernandes, Rajeshwari Punekar, et al.. (2019). Real-world Treatment Patterns Among Patients with Unresected Stage III Non-Small-Cell Lung Cancer. Future Oncology. 15(25). 2943–2953. 25 indexed citations

12.

Bridges, John F. P., Melissa Pavilack, Emuella Flood, et al.. (2019). Patient Preferences for Attributes of Tyrosine Kinase Inhibitor Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Future Oncology. 15(34). 3895–3907. 13 indexed citations

13.

Lynch, Julie A., Michael J. Kelley, Kyung Min Lee, et al.. (2019). An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.. Journal of Clinical Oncology. 37(27_suppl). 318–318.

14.

Nadler, Eric, et al.. (2018). MA08.06 Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases. Journal of Thoracic Oncology. 13(10). S383–S383. 1 indexed citations

15.

Subramanian, Janakiraman, et al.. (2018). P2.15-26 Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated with EGFR-TKIs. Journal of Thoracic Oncology. 13(10). S827–S827.

16.

Chiang, Anne C., Melissa Pavilack, François Laliberté, et al.. (2018). MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs. Journal of Thoracic Oncology. 13(10). S410–S411. 14 indexed citations

17.

Nadler, Eric, et al.. (2018). Treatment Patterns and Clinical Outcomes Among Metastatic Non–Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. Clinical Lung Cancer. 19(4). 360–370. 38 indexed citations

18.

Parikh, Rohan, Kimmie McLaurin, Andrea V. Margulis, et al.. (2017). Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States. Infectious Diseases and Therapy. 6(4). 477–486. 21 indexed citations

19.

Pavilack, Melissa, et al.. (2017). Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants. Infectious Diseases and Therapy. 7(1). 121–134. 12 indexed citations

20.

Fernandes, Ancilla W., et al.. (2017). Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. Journal of Medical Economics. 21(2). 192–200. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact